focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

10 Oct 2011 08:21

RNS Number : 8579P
PuriCore Plc
10 October 2011
 



 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

PURICORE PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

x

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

STEWART NEWTON

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

22nd SEPTEMBER 2011

6. Date on which issuer notified:

6th OCTOBER 2011

7. Threshold(s) that is/are crossed orreached: vi, vii

4%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

ORDINARY

871,732

871,732

347,903

347,903

 

673,829

 

1.39%

2.69%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

1,021,732

 

4.09%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Stewart Newton is a major shareholder in Sussex Research Ltd, which owns Sussex Trading Company Ltd.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

15. Contact telephone number:

 

Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Stewart Newton/Sussex Trading Co Ltd

Contact address

(registered office for legal entities)

 

6th Floor, Elizabeth House, 39 York Road, London SE1 7NQ

Phone number & email

 

0207 961 1428 sn@realreturn.com

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Sara Lowne

Contact address

 

6th Floor, Elizabeth House, 39 York Road, London SE1 7NQ

Phone number & email

 

0207 961 1428 sjlowne@stsllp.com

 

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

PA

C: Additional information

Stewart Worth Newton has a beneficial interest in Sussex Trading Co Ltd. Stewart Newton owns 347,903 ordinary shares in his own name (1.39%) and Sussex Trading Co Ltd owns 673,829 ordinary shares (2.69%)

For notes on how to complete form TR-1 please see the FSA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFFSSWSFFSEES
Date   Source Headline
9th Oct 20185:02 pmRNSForm 8.3 - Realm Therapeutics PLC
9th Oct 201810:13 amRNSForm 8.3 - Realm Therapeutics plc
5th Oct 20186:08 pmBUSForm 8.3 - Realm Therapeutics PLC
5th Oct 20182:00 pmRNSFORM 8.3 - Realm Therapeutics Plc
4th Oct 20188:57 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics plc
2nd Oct 201810:43 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics PLC
1st Oct 20187:00 amRNSProvides Update on Timing of Formal Sale Process
24th Sep 20189:59 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
21st Sep 201811:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Sep 20185:06 pmRNSForm 8.3 - Realm Therapeutics plc
20th Sep 20185:06 pmRNSForm 8.3 - Realm Therapeutics plc
20th Sep 20183:16 pmRNSHolding(s) in Company
20th Sep 201811:53 amRNSForm 8.3 - REALM THERAPEUTICS PLC
20th Sep 201811:18 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
19th Sep 20184:31 pmRNSForm 8 (OPD) - Realm Therapeutics plc
19th Sep 201811:11 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
18th Sep 201812:02 pmRNSForm 8.3 - Realm Therapeutics PLC
18th Sep 201811:19 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
17th Sep 20187:00 amRNSCorporate Update and Hiring of Advisor
20th Aug 201811:00 amRNSPrice Monitoring Extension
20th Aug 20187:00 amRNSBlock listing Interim Review
15th Aug 20184:35 pmRNSPrice Monitoring Extension
14th Aug 20187:10 amRNSHalf-year Report
8th Aug 20187:00 amRNSPresents at Wedbush PacGrow Healthcare Conference
7th Aug 20187:00 amRNSNotice of Results
16th Jul 20185:33 pmRNSHolding(s) in Company
10th Jul 20187:00 amRNSPre-Clinical Study in Atopic Dermatitis
4th Jul 20187:00 amRNSInstructions for Exchanging Ordinary Shares
4th Jul 20187:00 amRNSSEC registration effective NASDAQ listing approved
14th Jun 201810:54 amRNSResult of AGM
31st May 20187:00 amRNSRealm to Present at June Investor Conferences
24th May 20187:00 amRNSEnrollment complete for Phase 2 study of PR022
23rd May 20187:00 amRNSFiling with US SEC to Facilitate Nasdaq Listing
21st May 20187:00 amRNSData Presentation at IID 2018
2nd May 201812:39 pmRNSAnnual Financial Report Available
2nd May 20187:00 amRNSFinal Results
2nd May 20187:00 amRNSRealm Files Registration for Nasdaq Listing of ADS
26th Apr 20182:32 pmRNSNotice of Results
12th Mar 20184:40 pmRNSSecond Price Monitoring Extn
12th Mar 20184:35 pmRNSPrice Monitoring Extension
12th Mar 20187:00 amRNSClinical Update including PR013 Phase II results
8th Mar 20187:00 amRNSPresenting at Cowen Healthcare Conference
27th Feb 20187:00 amRNSPatent portfolio strengthened with USPTO allowance
20th Feb 201812:00 pmRNSPresentation at RBC Healthcare Conference
16th Feb 20187:00 amRNSBlock listing Interim Review
15th Feb 20187:00 amRNSClinical and Business Update
2nd Jan 20187:00 amRNSPresents at 5th Annual Dermatology Summit
15th Dec 20177:00 amRNSDirector/PDMR Shareholding
12th Dec 20177:00 amRNSFirst Patient Dosed in Phase 2 Study of PR013
5th Dec 20177:00 amRNSFirst Patient Dosed in Phase 2 Study of PR022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.